Company
N4 Pharma plc
Headquarters: London, United Kingdom
Employees: 5
CEO: Mr. Nigel James Theobald
Market Cap
£3.1 Million
GBP as of July 1, 2025
US$4.3 Million
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. The company has a research collaboration with Nanomerics Limited to focus on the different formulations of Nuvec delivery system. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | £1,953 |
| EBITDA | £0 |
| Gross Profit TTM | £0 |
| Profit Margin | 0.00% |
| Operating Margin | -35338.49% |
| Quarterly Revenue Growth | % |
Stocks & Indices
N4 Pharma plc has the following listings and related stock indices.
Stock: LSE: N4P wb_incandescent